Determinants of visfatin in type 2 diabetes patients with diabetic kidney disease: Relationship to inflammation, adiposity and undercarboxylated osteocalcin

References

• Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456–69.
   PubMed Web of Science ®Google Scholar
• Andrade-Oliveira V, Câmara NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res 2015;2015:68161.
   Web of Science ®Google Scholar
• Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013;18:12.
   PubMed Web of Science ®Google Scholar
• Yun MR, Seo JM, Park HY. Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells. Cell Signal 2014;26:705–15.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748–58.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Yang WL, Jacob A, Aziz M, Matsuo S, Matsutani T, Uchida E, Wang P. FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice via NF-κB pathway. Ann Surg 2014;259:1007–17.
   PubMed Web of Science ®Google Scholar
• Montecucco F, Bauer I, Braunersreuther V, Bruzzone S, Akhmedov A, Lüscher FT, Speer T, Poggi A, Mannino E, Pelli G, Galan K, Bertolotto M, Lenglet S, Garuti A, Montessuit C, Lerch R, Pellieux C, Vuilleumier N, Dallegri F, Mage J, Sebastian C, Mostoslavsky R, Gayet-Ageron A, Patrone F, Mach F, Nencioni A. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxidant Redox Signal 2013;18:630–41.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–30.
   PubMed Web of Science ®Google Scholar
• Brown JE, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST, Dunmore SJ, Randeva HS. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010;44:171–8.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S64–73.
   PubMed Web of Science ®Google Scholar
• Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2009;29:31–5.
   PubMed Web of Science ®Google Scholar
• Nüsken KD, Petrasch M, Rauh M, Stöhr W, Nüsken E, Schneider H, Dötsch J. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009;24:2832–8.
   PubMed Web of Science ®Google Scholar
• Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis. Metabol 2008;57:1414–21.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008;23:959–65.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008;23:1621–7.
   PubMed Web of Science ®Google Scholar
• Kang YS, Song HK, Lee MH, Ko GJ, Cha DR. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract 2010;89:141–9.
   PubMed Web of Science ®Google Scholar
• Mahmood N, Junejo AM, Jamal Q, Awan R. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc 2010;60:922–6.
   PubMed Web of Science ®Google Scholar
• Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010;15:225–9.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007;49:237–44.
   PubMed Web of Science ®Google Scholar
• Huang Q, Guo Y, Zeng H, Xie W, Yan H, Ding H. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 2011;36:93–100.
   PubMed Web of Science ®Google Scholar
• Boini KM, Zhang C, Xia M, Han WQ, Brimson C, Poklis JL, Li PL. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010;1801:1294–304.
   PubMed Web of Science ®Google Scholar
• Hye KS, Mi HL, Bo KK, Yun GP, Gang JK, Young SK, Jee YH, Sang YH, Kum HH, Hyoung KK, Dae RC. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008;295:F1485–94.
   Google Scholar
• Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, Han KH, Kim HK, Cha DR. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kidney Int 2010;78:170–81.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metab Clin Exp 2006;55:1645–52.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
   PubMed Web of Science ®Google Scholar
• Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318–27.
   PubMed Web of Science ®Google Scholar
• Skop V, Kontrová K, Zídek V, Pravenec M, Kazdová L, Mikulík K, Sajdok J, Zídková J. Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiol Res 2010;59:615–18.
   PubMed Web of Science ®Google Scholar
• Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, Dietz E, Norman K, Buning C, Winklhofer-Roob BM, Lochs H, Ockenga J. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009;25:172–81.
   PubMed Web of Science ®Google Scholar
• Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007;3:716–24.
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology (Carlton) 2010;15:190–6.
   PubMed Web of Science ®Google Scholar
• Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010;21:530–5.
   PubMed Web of Science ®Google Scholar
• Mu J, Feng B, Ye Z, Yuan F, Zeng W, Luo Z, Qi W. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011;24:177–84.
   PubMed Web of Science ®Google Scholar
• Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013;2013:946427.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen M, Zhang W. Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013;38:553–9.
   PubMedGoogle Scholar
• Lu YC1, Hsu CC, Yu TH, Wang CP, Lu LF, Hung WC, Chiu CA, Chung FM, Lee YJ, Tsai IT. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis 2013;7:446–52.
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, Vatish M, Lewinski A, Prelevic GM, Randeva HS. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033–7.
   PubMed Web of Science ®Google Scholar
• Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009;25:241–5.
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9.
   PubMed Web of Science ®Google Scholar
• Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernandez-Real JM. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871–5.
   PubMed Web of Science ®Google Scholar
• Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006;43:548–9.
   PubMed Web of Science ®Google Scholar
• Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, Dabrowski P, Skorupa A. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131–4.
   PubMed Web of Science ®Google Scholar
• Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008;79:412–18.
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006;114:544–8.
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165–70.
   PubMed Web of Science ®Google Scholar
• Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;76:119–25.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Retraction. Science 2007;318:565.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363–75.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Dong W, Qian L, Wu J, Peng Y. Visfatin inhibits apoptosis of pancreatic β-cell line, MIN6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway. J Mol Endocrinol 2011;47:13–21.
   PubMed Web of Science ®Google Scholar
• Gouranton E, Romier B, Marcotorchino J, Tourniaire F, Astier J, Peiretti F, Landrier JF. Visfatin is involved in TNFα-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte 2014;3:180–9.
   PubMedGoogle Scholar
• Karakan S, Sezer S, Özdemir Acar FN, Haberal M. The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients. Ren Fail 2012;34:732–7.
   PubMed Web of Science ®Google Scholar
• Erten Y, Ebinç FA, Ebinç H, Paşaoğlu H, Demirtaş C, Taçoy G, Koç E, Derici U, Reis KA, Bali M, Arinsoy T, Sindel S. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2008;30:617–23.
   PubMed Web of Science ®Google Scholar
• Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M, Brzozowska A, Mossakowska M, Skalska A, Wiecek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects. Clin Chem Lab Med 2015;53:793–9.
   PubMed Web of Science ®Google Scholar
• Briana DD, Boutsikou M, Boutsikou T, Malamitsi-Puchner A. Associations of novel adipocytokines with bone biomarkers in intra uterine growth-restricted fetuses/neonates at term. J Matern Fetal Neonatal Med 2014;27:984–8.
   PubMed Web of Science ®Google Scholar
• Briana DD, Boutsikou M, Boutsikou T, Malamitsi-Puchner A. Relationships between maternal novel adipocytokines and bone biomarkers in complicated by gestational hypertensive disorders and normal pregnancies. J Matern Fetal Neonatal Med 2013;26:1219–22.
   PubMed Web of Science ®Google Scholar
• Blogowski W, Serwin K, Budkowska M, Salata D, Dolegowska B, Lokaj M, Prowans P, Starzynska T. Clinical analysis of systemic and adipose tissue levels of selected hormones/adipokines and stromal-derived factor-1. J Biol Regul Homeost Agents 2012;26:607–15.
   PubMed Web of Science ®Google Scholar
• Sucunza N, Barahona MJ, Resmini E, Fernández-Real JM, Ricart W, Farrerons J, Rodríguez Espinosa J, Marin AM, Puig T, Webb SM. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009;94:3889–96.
   PubMed Web of Science ®Google Scholar
• Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C, Petramala L, Minisola S, D'erasmo E, Letizia C. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2011;34:e12–15.
   PubMed Web of Science ®Google Scholar
• Pepene CE. Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits. J Ovarian Res 2013;6:4.
   PubMed Web of Science ®Google Scholar
• Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabolism: a two-way street. Arch Biochem Biophys 2010;503:2–10.
   PubMed Web of Science ®Google Scholar
• Tan BK, Chen J, Brown J, Adya R, Ramanjaneya M, Menon V, Bailey CJ, Lehnert H, Randeva HS. In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Endocrinology 2009;150:3530–9.
   PubMed Web of Science ®Google Scholar
• Baker-LePain JC, Nakamura MC, Lane NE. Effects of inflammation on bone: an update. Curr Opin Rheumatol 2011;23:389–95.
   PubMed Web of Science ®Google Scholar
• Garanty-Bogacka B, Syrenicz M, Rać M, Krupa B, Czaja-Bulsa G, Walczak M, Sowińska-Przepiera E, Syrenicz A. Association between serum osteocalcin, adiposity and metabolic risk in obese children and adolescents. Endokrynol Pol 2013;64:346–52.
   PubMed Web of Science ®Google Scholar
• Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013;17:1631–5.
   PubMed Web of Science ®Google Scholar
• Shea MK, Booth SL, Massaro JM, Jacques PF, D'agostino RB Sr, Dawson-Hughes B, Ordovas JM, O'donnell CJ, Kathiresan S, Keaney JF Jr, Vasan RS, Benjamin EJ, Vitamin K, Vitamin D. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol 2008;167:313–20.
   PubMed Web of Science ®Google Scholar
• Mihu D, Georgescu C, Mihu C, Costin N, Blaga L, Pop R. High maternal serum leptin and interleukin-6 levels in pre-eclampsia and relationships with clinical and metabolical parameters of disease severity and pregnancy outcome. Acta Endo (Buc) 2009;5:49–60.
   Web of Science ®Google Scholar
• Zhou H, Yang X, Wang N, Zhang Y, Cai G. Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells. Mol Cell Endocrinol 2007;270:17–22.
   PubMed Web of Science ®Google Scholar
• Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007;80:201–10.
   PubMed Web of Science ®Google Scholar